Advertisement

Biodel Inc., a diabetes-focused therapeutics firm in Danbury, Conn., is ushering two new insulin drug candidates into Phase 1 clinical studies, the company announced today.

BIOD-105 and BIOD-107, the company’s recombinant human insulin formulations, will be tested in trials of 18 patients with Type 1 diabetes. The drug candidates are being described as meal-time insulin drugs intended to have quicker insulin action than current comparable drugs on the market. The Phase 1 trial is planned to be completed by the third quarter of 2011, and will evaluate the pharmacokinetic, pharmacodynamic and tolerability of BIOD-105 and BIOD-107, relative to Humalogic injections.

SOURCE

Advertisement
Advertisement